Pacira BioSciences (PCRX) Income from Continuing Operations (2010 - 2026)
Pacira BioSciences (PCRX) posted quarterly Income from Continuing Operations of 2916000.0 for Q1 2026, down 39.4% year-over-year from 4812000.0 in Q1 2025, and up 78.13% quarter-over-quarter from 1637000.0 in Q4 2025.
Pacira BioSciences (PCRX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Pacira BioSciences' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 2916000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 39.4% year-over-year to 2916000.0; the TTM figure through Mar 2026 stood at 5138000.0 (up 104.95% YoY), while the FY2025 annual figure was 7034000.0, up 107.07% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 2916000.0, up from 1637000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 25763000.0 in Q2 2023, with the low at 143466000.0 in Q3 2024.
- The 5-year median for Income from Continuing Operations is 5432000.0 (2025), against an average of 1867411.76.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations surged 1666.81% in 2023, then sank 1421.29% in 2024.
- Pacira BioSciences' Income from Continuing Operations stood at 10102000.0 in 2022, then surged by 346.19% to 24870000.0 in 2023, then tumbled by 35.5% to 16041000.0 in 2024, then sank by 89.79% to 1637000.0 in 2025, then surged by 78.13% to 2916000.0 in 2026.
- Business Quant data shows PCRX's Income from Continuing Operations at 2916000.0 in Q1 2026, 1637000.0 in Q4 2025, and 5432000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Pacira BioSciences | 946.10 Mn | 695.07 Mn | 148.24 Mn | 4.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.65 Mn |
| Mar 31, 2026 | 2.92 Mn |
| Dec 31, 2025 | 1.64 Mn |
| Sep 30, 2025 | 5.43 Mn |
| Jun 30, 2025 | -4.85 Mn |
| Mar 31, 2025 | 4.81 Mn |
| Dec 31, 2024 | 16.04 Mn |
| Sep 30, 2024 | -143.47 Mn |
| Jun 30, 2024 | 18.89 Mn |
| Mar 31, 2024 | 8.98 Mn |
| Dec 31, 2023 | 24.87 Mn |
| Sep 30, 2023 | 10.86 Mn |
| Jun 30, 2023 | 25.76 Mn |
| Mar 31, 2023 | -19.54 Mn |
| Dec 31, 2022 | -10.10 Mn |
| Sep 30, 2022 | -693,000.00 |
| Jun 30, 2022 | 19.88 Mn |
| Mar 31, 2022 | 6.83 Mn |
| Dec 31, 2021 | -5.13 Mn |
| Sep 30, 2021 | 17.66 Mn |